Browse by author
Lookup NU author(s): Alice Bradbury, Sally Hall, Professor Nicola CurtinORCiD, Dr Yvette DrewORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2019. The DNA damage response (DDR) machinery is responsible for detecting DNA damage, pausing the cell cycle and initiating DNA repair. Ataxia telangiectasia and Rad3-related (ATR) protein is a key kinase at the heart of the DDR, responsible for sensing replication stress (RS) and signalling it to S and G2/M checkpoints to facilitate repair. In cancer, loss of G1 checkpoint control and activation of oncogenes that drive replication, result in cancer cells more likely to enter S phase with increased RS. These cancer cells become more reliant on their S and G2/M checkpoints, making this an attractive anti-cancer target. Targeting ATR is the focus of many oncology drug pipelines with a number of potent, selective ATR inhibitors developed, four (M6620, M4344, AZD6738 and BAY1895344) are currently in clinical development. Here we summarise the pre-clinical data supporting the use of ATR inhibitors as monotherapy and in combination with chemotherapy, radiotherapy and novel targeted agents such as PARP inhibitors. We discuss the current clinical trial data and the challenges of taking ATR inhibitors into the clinic and of identifying biomarkers to aid patient selection.
Author(s): Bradbury A, Hall S, Curtin N, Drew Y
Publication type: Review
Publication status: Published
Journal: Pharmacology and Therapeutics
Year: 2020
Volume: 207
Print publication date: 01/03/2020
Online publication date: 11/12/2019
Acceptance date: 02/04/2018
ISSN (print): 0163-7258
ISSN (electronic): 1879-016X
Publisher: Elsevier Inc.
URL: https://doi.org/10.1016/j.pharmthera.2019.107450
DOI: 10.1016/j.pharmthera.2019.107450
PubMed id: 31836456
